NEW YORK (GenomeWeb) – CareDx reported after the close of the market on Thursday that its second quarter revenues rose 12 percent, mostly due to a 16 percent increase in revenues from its non-invasive heart transplant rejection test AlloMap.
For the three months ended June 30, the firm reported total revenues of $12.0 million, up from $10.7 million in Q2 2016, and beating the average Wall Street estimate for revenues of $11.8 million.